Marker Therapeutics, Inc. (MRKR) Stock Score, Valuation & Financial Research

Marker Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MRKR

Marker Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.01. These figures are a research snapshot, not a buy or sell recommendation.

What Marker Therapeutics, Inc. does

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Marker Therapeutics is a clinical-stage immuno-oncology company that focuses on the development and commercialization of novel T cell-based immunotherapies. The company currently operates as a research and development entity and does not generate revenue from product sales, relying instead on capital raises and potential future licensing or collaboration agreements to fund its operations.

Products and services

  • The company's primary product candidates include multi-antigen targeted T cell therapies (MAR-T), such as MT-601 for lymphoma and other hematological and solid tumor indications.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Peptide vendors — The company utilizes third-party vendors for the supply of peptides used in the manufacturing of its MAR-T cell products; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Baylor College of Medicine (BCM) — The company holds an exclusive worldwide license agreement with BCM for rights to certain T cell therapy technologies. Source

Business strengths to evaluate

  • Favorable safety profile and tolerability of MAR-T cell therapies observed in clinical trials Source

Business risks and research considerations

  • Substantial risks and uncertainties associated with clinical development and regulatory approval processes Source

Sources: Company research source · Baylor College of Medicine (BCM) · Peptide vendors

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MRKR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.01
Market capitalization:
16.84M (currency not supplied)
Revenue:
USD 1.23M
Net income:
USD -8.71M
Free cash flow:
USD -12.01M
Cash:
USD 11.33M
Total debt:
USD 0.00
EPS:
USD -0.48

What stands out

  • Free cash flow is USD -12.01M, negative for the stored period.
  • The balance sheet shows USD 11.33M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -974.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -706.2% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 11.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MRKR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MRKR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MRKR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MRKR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MRKR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MRKR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.